Skip to main content
. 2020 Jan 17;10:603. doi: 10.1038/s41598-019-57283-0

Figure 6.

Figure 6

Analysis of chimeric multiepitope vaccine efficacy. (A) Cumulative mortality for chimeric multiepitope DNA vaccines and recombinant protein vaccines compared with that for the FKC (positive control) and pcDNA3.1(+) (negative control) groups. (B) Relative percentage survival (RPS) of chimeric multiepitope vaccine groups based on that of the control pcDNA3.1 group at 21 days post challenge. Data are represented as the means ± SDs (n = 3). Statistical analysis was performed via a one way ANOVA, compared with the control group (pcDNA3.1). The different letters above the bars indicate significant differences (P < 0.05).